Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556793 | 0.88 | MEN1 (0.64) | MAOASCN8ACHRM2DRD4MEN1 | |
| Hydrochloric Acid SCHEMBL30321036 | 0.86 | L3MBTL1 (0.64) | MAOASCN8ACHRM2DRD4MEN1 | |
| SCHEMBL23105183 | 0.83 | CHRM2 (0.51) | SCN8ACHRM2MEN1KMT2ATDP1 | |
| SCHEMBL12296730 | 0.83 | SIGMAR1 (0.70) | DRD4MEN1KMT2ASIGMAR1DRD2 | |
| SCHEMBL3857148 | 0.81 | L3MBTL1 (0.54) | SCN8ACHRM2TDP1KDM4E | |
| SCHEMBL21657638 | 0.81 | DRD4 (0.56) | MAOACHRM2DRD4MEN1KMT2A | |
| SCHEMBL893154 | 0.81 | MAOA (0.86) | MAOASCN8ACHRM2DRD4MEN1 | |
| SCHEMBL4932707 | 0.81 | MAOA (0.95) | MAOACHRM2MEN1KMT2ATDP1 | |
| SCHEMBL7316637 | 0.81 | MAOA (0.64) | MAOASCN8ACHRM2DRD4MEN1 | |
| SCHEMBL10488208 | 0.81 | SIGMAR1 (0.65) | MAOACHRM2TDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| US-8921576-B2 | Spiroindoline compound, and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| EP-2781521-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-4918074-A | CALCIUM ANTAGONISTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0217142-A2 | A polyazaheterocyclic compound | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-04-08 | — | — | EP | disclosed |
| US-4102639-A | GOOD SOLVENT SOLUBILITY | CIBA-GEIGY CORPORATION (US) | 1978-07-25 | — | — | US | disclosed |
| US-3968298-A | Process for imparting to natural keratin-containing material a permanent finish rendering the material resistant to damage by insects | CIBA-GEIGY CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | GCKR, GCK, GALK1 | MAOA 4423/4885SCN8A 729/4885CHRM2 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.